

Osteoporosis - Pipeline Review, H1 2020

https://marketpublishers.com/r/OE41713576BEN.html

Date: April 2020

Pages: 353

Price: US\$ 2,000.00 (Single User License)

ID: OE41713576BEN

Abstracts

Osteoporosis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and



discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 8, 7, 22, 4, 63, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and



understand from the know-how what drove them from pipeline.



Contents

Introduction

Osteoporosis - Overview

Osteoporosis - Therapeutics Development

Osteoporosis - Therapeutics Assessment

Osteoporosis - Companies Involved in Therapeutics Development

Osteoporosis - Drug Profiles

Osteoporosis - Dormant Projects

Osteoporosis - Discontinued Products

Osteoporosis - Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Osteoporosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Osteoporosis - Pipeline by Ablynx NV, H1 2020

Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2020

Osteoporosis - Pipeline by Addpharma Inc, H1 2020

Osteoporosis - Pipeline by Aerami Therapeutics, H1 2020

Osteoporosis - Pipeline by Affilogic SAS, H1 2020

Osteoporosis - Pipeline by AgeX Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by AlphaMab Co Ltd, H1 2020



Osteoporosis - Pipeline by Altum Pharmaceuticals Inc, H1 2020

Osteoporosis - Pipeline by Amgen Inc, H1 2020

Osteoporosis - Pipeline by Aryogen Pharmed Co, H1 2020

Osteoporosis - Pipeline by Axsome Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by Bainan Biotech ApS, H1 2020

Osteoporosis - Pipeline by BIOCND Inc, H1 2020

Osteoporosis - Pipeline by Biosion Inc, H1 2020

Osteoporosis - Pipeline by Bone Biologics Corp, H1 2020

Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2020

Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2020

Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2020

Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020

Osteoporosis - Pipeline by Citragen Pharmaceuticals Inc, H1 2020

Osteoporosis - Pipeline by Corium, Inc., H1 2020

Osteoporosis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020

Osteoporosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020

Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2020

Osteoporosis - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2020

Osteoporosis - Pipeline by Eli Lilly and Co, H1 2020

Osteoporosis - Pipeline by EndoCeutics Inc. H1 2020

Osteoporosis - Pipeline by Enesi Pharma Ltd, H1 2020

Osteoporosis - Pipeline by Entera Bio Ltd, H1 2020

Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2020

Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2020

Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2020

Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2020

Osteoporosis - Pipeline by Galapagos NV, H1 2020

Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H1 2020

Osteoporosis - Pipeline by GlycoNex Inc, H1 2020

Osteoporosis - Pipeline by GPN Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2020

Osteoporosis - Pipeline by Helixmith Co Ltd, H1 2020

Osteoporosis - Pipeline by Hengenix Biotech Inc, H1 2020

Osteoporosis - Pipeline by Histide AG, H1 2020

Osteoporosis - Pipeline by HNB Therapeutics LLC, H1 2020

Osteoporosis - Pipeline by Hualan Biological Engineering Inc, H1 2020

Osteoporosis - Pipeline by Huons Co Ltd, H1 2020



Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2020

Osteoporosis - Pipeline by IMGENEX India Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Immunwork Inc, H1 2020

Osteoporosis - Pipeline by InnoPharmaScreen Inc, H1 2020

Osteoporosis - Pipeline by Innovent Biologics Inc, H1 2020

Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020

Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2020

Osteoporosis - Pipeline by Ipsen SA, H1 2020

Osteoporosis - Pipeline by JHL Biotech Inc, H1 2020

Osteoporosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Osteoporosis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020

Osteoporosis - Pipeline by Keros Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by Kolmar Pharma Co Ltd, H1 2020

Osteoporosis - Pipeline by Kyoto Pharmaceutical Industries Ltd, H1 2020

Osteoporosis - Pipeline by LBL Biotech Corp, H1 2020

Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2020

Osteoporosis - Pipeline by Lupin Ltd, H1 2020

Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2020

Osteoporosis - Pipeline by Max Biopharma Inc, H1 2020

Osteoporosis - Pipeline by Merck & Co Inc, H1 2020

Osteoporosis - Pipeline by Mesentech Inc, H1 2020

Osteoporosis - Pipeline by Metabolab Inc, H1 2020

Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by Nano Intelligent Biomedical Engineering Corp, H1 2020

Osteoporosis - Pipeline by Nanomedic Inc, H1 2020

Osteoporosis - Pipeline by NeuClone Pty Ltd, H1 2020

Osteoporosis - Pipeline by NovMetaPharma Co Ltd, H1 2020

Osteoporosis - Pipeline by Omeros Corp, H1 2020

Osteoporosis - Pipeline by Ortho Regenics Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2020

Osteoporosis - Pipeline by Pfenex Inc, H1 2020

Osteoporosis - Pipeline by PhytoHealth Corp, H1 2020

Osteoporosis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Osteoporosis - Pipeline by R Pharm, H1 2020

Osteoporosis - Pipeline by Regenerative Arthritis & Bone Medicine Inc, H1 2020

Osteoporosis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Ribomic Inc, H1 2020

Osteoporosis - Pipeline by Sandoz International GmbH, H1 2020

Osteoporosis - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H1 2020



Osteoporosis - Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, H1 2020

Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020

Osteoporosis - Pipeline by Shanghai Junshi Bioscience Co Ltd, H1 2020

Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2020

Osteoporosis - Pipeline by Shin Poong Pharm Co Ltd, H1 2020

Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Suzhou Stainwei Biotech Inc, H1 2020

Osteoporosis - Pipeline by Taithera Inc, H1 2020

Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020

Osteoporosis - Pipeline by Tritech Biopharmaceuticals Co Ltd, H1 2020

Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2020

Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2020

Osteoporosis - Pipeline by USV Pvt Ltd, H1 2020

Osteoporosis - Pipeline by Vibe Pharmaceuticals LLC, H1 2020

Osteoporosis - Pipeline by Vidasym Inc, H1 2020

Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2020

Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2020

Osteoporosis - Pipeline by Zosano Pharma Corp. H1 2020

Osteoporosis - Dormant Projects, H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..1), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..2), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..3), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..4), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..5), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..6), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..7), H1 2020

Osteoporosis - Dormant Projects, H1 2020 (Contd..8), H1 2020

Osteoporosis - Discontinued Products, H1 2020

Osteoporosis - Discontinued Products, H1 2020 (Contd..1), H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development for Osteoporosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Ablynx NV

Abreos Biosciences Inc

Addpharma Inc

Aerami Therapeutics

Affilogic SAS

AgeX Therapeutics Inc

AlphaMab Co Ltd

Altum Pharmaceuticals Inc

Amgen Inc

Aryogen Pharmed Co

Axsome Therapeutics Inc

Bainan Biotech ApS

BIOCND Inc

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cellatoz Therapeutics Inc

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Citragen Pharmaceuticals Inc



Corium, Inc.

CSPC Pharmaceutical Group Ltd

Daewoong Pharmaceutical Co Ltd

Dong Wha Pharma Co Ltd

Dongkook Pharmaceutical Co Ltd

Eli Lilly and Co

EndoCeutics Inc

Enesi Pharma Ltd

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Epygen Biotech Pvt Ltd

Evgen Pharma Plc

Galapagos NV

Genor BioPharma Co Ltd

GlycoNex Inc

GPN Therapeutics Inc

Haoma Medica Ltd

Helixmith Co Ltd

Hengenix Biotech Inc

Histide AG

HNB Therapeutics LLC

Hualan Biological Engineering Inc

Huons Co Ltd

Huons Global Co Ltd

IMGENEX India Pvt Ltd

Immunwork Inc

InnoPharmaScreen Inc

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Keros Therapeutics Inc

Kolmar Pharma Co Ltd

Kyoto Pharmaceutical Industries Ltd



LBL Biotech Corp

Lead Discovery Center GmbH

Lupin Ltd

Luye Pharma Group Ltd

Max Biopharma Inc

Merck & Co Inc

Mesentech Inc

Metabolab Inc

Millendo Therapeutics Inc

Nano Intelligent Biomedical Engineering Corp

Nanomedic Inc

NeuClone Pty Ltd

NovMetaPharma Co Ltd

Omeros Corp

Ortho Regenics Pvt Ltd

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

Qilu Pharmaceutical Co Ltd

R Pharm

Regenerative Arthritis & Bone Medicine Inc

Reliance Life Sciences Pvt Ltd

Ribomic Inc

Sandoz International GmbH

Shandong Danhong Pharmaceutical Co Ltd

Shanghai Biomabs Pharmaceuticals Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong Pharm Co Ltd

Stelis Biopharma Pvt Ltd

Suzhou Stainwei Biotech Inc

Taithera Inc

Terpenoid Therapeutics Inc

The National Institute for Biotechnology in the Negev Ltd

Tritech Biopharmaceuticals Co Ltd

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

USV Pvt Ltd



Vibe Pharmaceuticals LLC Vidasym Inc Viking Therapeutics Inc Yooyoung Pharm Co Ltd Zosano Pharma Corp



I would like to order

Product name: Osteoporosis - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/OE41713576BEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/OE41713576BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| Email: | |
|---------------|---------------------------|
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970